$ 2.45
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Very low or no dividends
About
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment...
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers.
Target Price
The average target price of EDAP is 5.6 and suggests 130% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
